tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus] (Synonyms: H2N-Tyr-Leu-His-Val-Glu-Pro-Glu-Lys-Glu-Val-OH ) |
| カタログ番号GP10028 |
P53結合タンパク質フラグメント
Products are for research use only. Not for human use. We do not sell to patients.
![tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus] 化学構造](/media/struct/GP1/GP10028.png "tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus] 化学構造")
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
P53 is a sequence-specific DNA-binding oligomeric protein that can activate transcription from promoters bearing p53-binding sites. Whereas the activation region of p53 has been identified within the amino terminus, the location of the specific DNA-binding domain has not been reported1.
Tumor protein p53 binding protein (53BP1) has been identified in a yeast two hybrid screen as a protein that interacts with the central DNA-binding domain of p532. Similar to breast cancer susceptibility gene 13, 4 (BRCA1; 53BP1 enhances p53-dependent transcription5. Interestingly, the COOH terminus of 53BP1 contains tandem BRCA1 COOH terminus (BRCT) motifs.
53BP1 becomes hyperphosphorylated and rapidly relocates to the sites of DNA strand breaks in response to ionizing radiation. 53BP1 foci formation is reduced in ATM-deficient cells and can be inhibited by wortmannin in ATM wild-type cells. Moreover, radiation-induced hyperphosphorylation of 53BP1 is absent in cells treated with wortmannin, as well as in ATM-deficient cells. 53BP1 participates in DNA damage-signaling pathways and is regulated by ATM after ?-radiation6.
References:
1.J.Bargonetti, J. J. Manfredi et al. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity wlien generated from wild-type but not from oncogenic mutant p53 protein, Genes Dev. 1993 7: 2565-2574
2.Iwabuchi, K., P.L. Bartel, B. Li, R. Marraccino, S. Fields (1994) Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. USA91:6098-6102
3.Ouchi, T., A.N. Monteiro, A. August, S.A. Aaronson, H. Hanafusa (1998) BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. USA95:2302-2306
4.Zhang, H., K. Somasundaram, Y. Peng, H. Tian, D. Bi, B.L. Weber, W.S. El-Deiry BRCA1 physically associates with p53 and stimulates its transcriptional activity Oncogene16199817131721
5.Iwabuchi, K., B. Li, H.F. Massa, B.J. Trask, T. Date, S. Fields(1998) Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J. Biol. Chem 273:26061-2606
6.Irene Rappold, Kuniyoshi Iwabuchi, Takayasu Date, and Junjie Chen Tumor Suppressor P53 Binding Protein 1 (53bp1) Is Involved in DNA Damage-Signaling Pathways. JCB vol. 153 no. 3 613-620
| Cas No. | SDF | ||
| 同義語 | H2N-Tyr-Leu-His-Val-Glu-Pro-Glu-Lys-Glu-Val-OH | ||
| Canonical SMILES | OC(C=C1)=CC=C1CC(N)C(NC(CC(C)C)C(NC(CC2=CN=CN2)C(NC(C(C)C)C(NC(CCC(O)=O)C(N3CCCC3C(NC(CCC(O)=O)C(NC(CCCCN)C(NC(CCC(O)=O)C(NC(C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
| Formula | C57H87N13O18 | M.Wt | 1242.38 |
| 溶解度 | ≥124.2mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8049 mL | 4.0245 mL | 8.0491 mL |
| 5 mM | 0.161 mL | 0.8049 mL | 1.6098 mL |
| 10 mM | 0.0805 mL | 0.4025 mL | 0.8049 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *